Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 6, 2014, Pages 437-443

  Salem, Ahmed Hamed ^a,b   Zhanel, George G ^c   Ibrahim, Safaa A ^d,e   Noreddin, Ayman M ^f,g  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Ain Shams University   (Egypt)

^c UNIVERSITY OF MANITOBA   (Canada)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e CAIRO UNIVERSITY   (Egypt)

^f HAMPTON UNIVERSITY   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Ceftobiprole; Intensive care unit; Methicillin resistant Staphylococcus aureus; Monte Carlo simulation; Vancomycin

Indexed keywords

CEFTOBIPROLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; TEICOPLANIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; CUMULATIVE FRACTION OF RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PROBABILITY OF TARGET ATTAINMENT; STATISTICAL PARAMETERS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; COMPUTER SIMULATION; CROSS INFECTION; DOSE RESPONSE; DRUG EFFECTS; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMPUTER SIMULATION; CROSS INFECTION; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTENSIVE CARE UNITS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN;

EID: 84901194839     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12195     Document Type: Article

References (61)

1. Clark NM, Hershberger E, Zervosc MJ, Lynch JP III. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr. Opin. Crit. Care 2003; 9: 403-12.
2. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005; 26: 166-74.
3. Jevons MP. Celbenin-resistant staphylococci. Br. Med. J. 1961; 1: 124-5.
4. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 2001; 61: 1-7.
5. Sista RR, Oda G, Barr J. Methicillin-resistant Staphylococcus aureus infections in ICU patients. Anesthesiol. Clin. North Am. 2004; 22: 405-35 vi.
6. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3, 051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J. Clin. Microbiol. 2001; 39: 3727-32.
7. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. 2002; 162: 2229-35.
8. Fowler VG Jr, Kong LK, Corey GR et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J. Infect. Dis. 1999; 179: 1157-61.
9. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 1991; 115: 674-80.
10. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333-9.
11. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 1990; 34: 1227-31.
12. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 2006; 42(Suppl 1): S40-50.
13. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr. Med. Res. Opin. 2010; 26: 571-88.
14. Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn. Microbiol. Infect. Dis. 2008; 61: 96-102.
15. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 2006; 54: 149-53.
16. Jones RN, Fritsche TR, Sader HS, Goldstein BP. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 2005; 17: 593-600.
17. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6, 000 clinical isolates. Diagn. Microbiol. Infect. Dis. 2004; 48: 137-43.
18. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 2000; 44: 3447-50.
19. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2, 789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 2001; 45: 1919-22.
20. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 2003; 47: 1689-93.
21. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 2003; 138: 135-42.
22. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 3-15.
23. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit. Care Med. 2006; 34: 2069-74.
24. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2008; 61: 246-53.
25. Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob. Agents Chemother. 2008; 52: 1430-7.
26. Zhanel GG, Decorby M, Nichol KA et al. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). Can. J. Infect. Dis. Med. Microbiol 2008; 19: 243-9.
27. Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW. Monte carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob. Agents Chemother. 2013; 57: 2047-53.
28. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther. 2006; 31: 447-54.
29. Vilay AM, Grio M, DePestel DD et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit. Care Med. 2011; 39: 19-25.
30. Boselli E, Breilh D, Caillault-Sergent A et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J. Antimicrob. Chemother. 2012; 67: 1207-10.
31. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 2004; 48: 1713-8.
32. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J. Clin. Pharmacol. 2009; 49: 465-76.
33. Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents Chemother. 2006; 50: 3701-7.
34. Lodise TP Jr, Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 2007; 51: 2378-87.
35. Kimko H, Xu X, Nandy P et al. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 2009; 53: 3371-4.
36. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 2007; 51: 1633.
37. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 2003; 47: 1598.
38. Andes D, Van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 2002; 46: 3484.
39. Meagher AK, Passarell JA, Cirincione BB et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 2007; 51: 1939.
40. Ambrose PG, Meagher AK, Passarell JA et al. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 2009; 63: 155-9.
41. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin. Microbiol. Infect. 2008; 14: 116.
42. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health-Sys. Pharm. 2009; 66: 82.
43. Mouton JW, Punt NC. Use of t > MIC to choose between different dosing regimens of beta-lactam antibiotics. J. Antimicrob. Chemother. 2001; 47: 500-1.
44. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 2005; 55: 601-7.
45. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 2000; 3: 515-21.
46. Gentry B, Blankinship D, Wainwright E. Oracle Crystal Ball User Manual 11.1. Denver, USA: Orcale. 2008.
47. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 2008; 46: 647-55.
48. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 2005; 41: 1407-15.
49. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 2003; 37: 1298-303.
50. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J. Clin. Pharmacol. 2008; 48: 1063-8.
51. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 2009; 49: 325-7.
52. Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006; 26: 129-34.
53. Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 2004; 48: 369.
54. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 2006; 166: 2138.
55. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004; 42: 2398-402.
56. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007; 44: 1208-15.
57. Daptomycin pharmacodynamics (PD) versus MRSA at various doses as assessed by a Monte Carlo prediction model [abstr]. Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December; 2001.
58. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24: 41-57.
59. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 2003; 52: 405.
60. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 2000; 44: 2991.
61. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 2004; 43: 925-42.